TP53的过表达与较差的生存率相关，但与老年急性髓系白血病患者对低甲基化药物反应降低无关。 - Suppr

Overexpression of TP53 is associated with poor survival, but not with reduced response to hypomethylating agents in older patients with acute myeloid leukaemia.

作者信息

van der Helm Lieke H, Berger Gerbrig, Diepstra Arjan, Huls Gerwin, Vellenga Edo

机构信息

Department of Haematology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.

Department of Pathology and Medical Biology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.

出版信息

Br J Haematol. 2017 Sep;178(5):810-812. doi: 10.1111/bjh.14166. Epub 2016 Jul 19.

DOI:10.1111/bjh.14166

PMID:27431572

Abstract

摘要

相似文献

Overexpression of TP53 is associated with poor survival, but not with reduced response to hypomethylating agents in older patients with acute myeloid leukaemia.

Br J Haematol. 2017 Sep;178(5):810-812. doi: 10.1111/bjh.14166. Epub 2016 Jul 19.

Hypomethylating agents super-responders: challenging the dogma of long-term remission for acute myeloid leukemia.

Ann Hematol. 2020 Jun;99(6):1411-1413. doi: 10.1007/s00277-020-04054-x. Epub 2020 May 6.

Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia?

Hematol Oncol. 2014 Mar;32(1):1-9. doi: 10.1002/hon.2046. Epub 2013 Mar 20.

CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine.

Leuk Lymphoma. 2018 Apr;59(4):821-828. doi: 10.1080/10428194.2017.1352089. Epub 2017 Jul 18.

Association between the TP53 Arg72Pro polymorphism and clinical outcomes in acute myeloid leukemia.

Haematologica. 2017 Feb;102(2):e43-e46. doi: 10.3324/haematol.2016.155069. Epub 2016 Oct 20.

Targeting acute myeloid leukemia with TP53-independent vosaroxin.

Future Oncol. 2017 Jan;13(2):125-133. doi: 10.2217/fon-2016-0300. Epub 2016 Sep 12.

TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.

Eur J Haematol. 2015 Apr;94(4):355-62. doi: 10.1111/ejh.12438. Epub 2014 Oct 1.

Predictive value of TP53 fluorescence in situ hybridization in cytogenetic subgroups of acute myeloid leukemia.

Leuk Lymphoma. 2011 Apr;52(4):642-7. doi: 10.3109/10428194.2010.551571. Epub 2011 Feb 16.

Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia.

Br J Haematol. 2019 Oct;187(2):e45-e48. doi: 10.1111/bjh.16166. Epub 2019 Aug 22.

Treatment of Elderly Patients With Acute Myeloid Leukemia.

Curr Treat Options Oncol. 2017 Jan;18(1):2. doi: 10.1007/s11864-017-0445-5.

引用本文的文献

Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS.

Blood Adv. 2020 Sep 22;4(18):4267-4277. doi: 10.1182/bloodadvances.2020002846.

Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia.

Ann Hematol. 2020 Jul;99(7):1551-1560. doi: 10.1007/s00277-020-04082-7. Epub 2020 Jun 6.

Clinical efficacy of decitabine in combination with standard-dose cytarabine, aclarubicin hydrochloride, and granulocyte colony-stimulating factor in the treatment of young patients with newly diagnosed acute myeloid leukemia.

Onco Targets Ther. 2019 Jun 28;12:5013-5023. doi: 10.2147/OTT.S200005. eCollection 2019.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Overexpression of TP53 is associated with poor survival, but not with reduced response to hypomethylating agents in older patients with acute myeloid leukaemia.

作者信息

van der Helm Lieke H, Berger Gerbrig, Diepstra Arjan, Huls Gerwin, Vellenga Edo

机构信息

Department of Haematology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.

Department of Pathology and Medical Biology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.

出版信息

Br J Haematol. 2017 Sep;178(5):810-812. doi: 10.1111/bjh.14166. Epub 2016 Jul 19.

DOI:10.1111/bjh.14166

PMID:27431572

Abstract

摘要

相似文献

Overexpression of TP53 is associated with poor survival, but not with reduced response to hypomethylating agents in older patients with acute myeloid leukaemia.

Br J Haematol. 2017 Sep;178(5):810-812. doi: 10.1111/bjh.14166. Epub 2016 Jul 19.

Hypomethylating agents super-responders: challenging the dogma of long-term remission for acute myeloid leukemia.

Ann Hematol. 2020 Jun;99(6):1411-1413. doi: 10.1007/s00277-020-04054-x. Epub 2020 May 6.

Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia?

Hematol Oncol. 2014 Mar;32(1):1-9. doi: 10.1002/hon.2046. Epub 2013 Mar 20.

CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine.

Leuk Lymphoma. 2018 Apr;59(4):821-828. doi: 10.1080/10428194.2017.1352089. Epub 2017 Jul 18.

Association between the TP53 Arg72Pro polymorphism and clinical outcomes in acute myeloid leukemia.

Haematologica. 2017 Feb;102(2):e43-e46. doi: 10.3324/haematol.2016.155069. Epub 2016 Oct 20.

Targeting acute myeloid leukemia with TP53-independent vosaroxin.

Future Oncol. 2017 Jan;13(2):125-133. doi: 10.2217/fon-2016-0300. Epub 2016 Sep 12.

TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.

Eur J Haematol. 2015 Apr;94(4):355-62. doi: 10.1111/ejh.12438. Epub 2014 Oct 1.

Predictive value of TP53 fluorescence in situ hybridization in cytogenetic subgroups of acute myeloid leukemia.

Leuk Lymphoma. 2011 Apr;52(4):642-7. doi: 10.3109/10428194.2010.551571. Epub 2011 Feb 16.

Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia.

Br J Haematol. 2019 Oct;187(2):e45-e48. doi: 10.1111/bjh.16166. Epub 2019 Aug 22.

Treatment of Elderly Patients With Acute Myeloid Leukemia.

Curr Treat Options Oncol. 2017 Jan;18(1):2. doi: 10.1007/s11864-017-0445-5.

引用本文的文献

Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS.

Blood Adv. 2020 Sep 22;4(18):4267-4277. doi: 10.1182/bloodadvances.2020002846.

Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia.

Ann Hematol. 2020 Jul;99(7):1551-1560. doi: 10.1007/s00277-020-04082-7. Epub 2020 Jun 6.

Onco Targets Ther. 2019 Jun 28;12:5013-5023. doi: 10.2147/OTT.S200005. eCollection 2019.

Overexpression of TP53 is associated with poor survival, but not with reduced response to hypomethylating agents in older patients with acute myeloid leukaemia.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Overexpression of TP53 is associated with poor survival, but not with reduced response to hypomethylating agents in older patients with acute myeloid leukaemia.

作者信息

机构信息

出版信息

相似文献

引用本文的文献